Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Key Takeaways GLP-1 drugs appear to help lower risk of obesity-related cancersThe drugs had a 41% lower risk of cancers ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...